huCLDN6-CHO-K is a recombinant protein derived from a Chinese Hamster Ovary (CHO) cell expression system, designed to mimic human Claudin-6 (CLDN6), a tight junction protein. Its primary application lies in cancer immunotherapy research and development. CLDN6 is overexpressed in various solid tumors, including testicular, ovarian, and endometrial cancers, while showing limited expression in healthy tissues, making it an attractive target for targeted therapies. This protein is used as a critical reagent in the development and testing of CLDN6-specific monoclonal antibodies, bispecific T-cell engagers (BiTEs), and chimeric antigen receptor (CAR) T-cell therapies. It enables researchers to validate target binding, assess antibody specificity, and optimize immune cell activation in preclinical models. Additionally, huCLDN6-CHO-K serves as an antigen source for immunization and antibody generation, supporting the discovery of novel immunotherapeutics. Due to its proper post-translational modifications and native-like conformation, it provides a reliable tool for functional assays, flow cytometry, and ELISA-based screening. Its use accelerates the evaluation of CLDN6-targeted drug candidates, contributing to the advancement of precision oncology treatments.